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Mitochondrial diseases encompass a broad range of devastating disorders that typically 
affect tissues with high-energy requirements. These disorders have been difficult to diagnose and 
research because of the complexity of mitochondrial genetics, and the large variability seen 
among patient populations. We have devised and carried out a mechanistic study to generate a 





disease is a multi-organ system disorder that depends heavily on the mutation burden seen within 
various tissues. Using new reprogramming and sequencing technologies, we were able to show 
that Leigh’s disease patient fibroblasts reprogrammed to induced pluripotent stem cells maintain 
the same level of mutation burden seen in the original patient cell line. Mutation burden was 
maintained through several passages and spontaneous differentiation. This cell based model 
could be useful for future pathogenesis studies, or therapeutic drug screenings in a patient and 
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A. Mitochondria Structure, Function, and Genetics 
 1. Structure 
Through DNA sequencing technologies and homology analysis, it is theorized that 
mitochondria arose from anα-Proteobacterial progenitor that formed an endosymbiotic 
relationship with an ancestral type of eukaryotic cell (95, 26). As such, mitochondria share a 
structural resemblance to their prokaryotic ancestors; possessing two separate and functionally 
unique membranes referred to as the outer membrane and inner membrane (41). The outer 
membrane separates the mitochondria from the cytoplasm and surrounds the inner membrane. 
Unlike the inner membrane, the outer membrane is rather porous. Ions and small-uncharged 
particles are able to flow through membrane protein porins, such as the voltage-dependent anion 
channel (4). The inner membrane is the site of the protein complexes responsible for generating 
the electrochemical gradient needed for adenosine triphosphate (ATP) synthesis in oxidative 
phosphorylation (41).  The inner membrane is subdivided into two contiguous regions known as 
the inner boundary membrane, which lies close to the outer membrane, and the cristae, which are 
folded invaginations of the inner membrane into the interior of the mitochondrion (60). A large 
complex of proteins known as the mitochondrial contact site and cristae organizing system is 
 
2 
Back To Table of Contents 
responsible for upholding the integrity of the folded cristae, and furthermore, maintaining the 
efficiency of energy production (23, 75, 61).  
The two membranes divide the mitochondrion into three compartments that serve 
different functions, and possess different protein components. The intermembrane space is the 
compartment between the outer and inner membrane, where much of the transportation 
machinery resides (56). The innermost compartment of the mitochondrion, the matrix, houses the 
double stranded circular mitochondrial deoxyribonucleic acid (mtDNA) molecule, as well as 
serves as the location for numerous enzymatic reactions, mitochondrial transcription, and 
mitochondrial translation carried out by the mitochondrial ribosomes, or mitoribosomes (81). 
The cristae delineate the final compartment, which is the cristae lumen. As the cristae membrane 
is the site for most of the protein complexes of the respiratory chain, the cristae lumen is the 
location where the proton gradient is formed (41). Complex V, or ATP synthase, is directly 
responsible for using the energy stored in the electrochemical proton gradient to produce ATP 
from adenosine diphosphate (ADP) and phosphate (12). Individual ATP synthases are composed 
of more than 20 individual proteins, and ATP synthases form supramolecular dimers and 
oligomers in long rows along the strongly curved regions of the cristae membrane (76). These 
dimers have been shown to be a universal feature among many mitochondria investigated. If 
certain subunits are removed from ATP synthases, dimers are unable to form, and the 
mitochondria lack the highly folded cristae that are typical of cristae morphology. From theses 
studies, it is clear that ATP synthase plays a role in generating the folded mitochondrial cristae. 
Given the importance of ATP synthase in the electron transport chain (ETC), any alterations in 
the complex itself or the supramolecular structure it forms could have functional implications on 
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the efficiency of oxidative phosphorylation and ultimately play a role in pathophysiological 
conditions (59, 76).   
 Different tissue and cell types show variability in mitochondrial arrangement and 
morphology. For instance, neuronal mitochondria are very dynamic and use various cytoskeletal 
components and specific motor proteins to move to different areas of the cell when needed (71). 
On the other hand, mitochondria of cardiomyocytes display a regular and fixed intracellular 
arrangement similar to a crystal (6). Mitochondria can also be found in close association with the 
endoplasmic reticulum (ER), which has functional implications that are discussed in a later 
section (66). In addition to variance among cell types, mitochondria can be dynamic in number 
and morphology within a single cell during times of development, cell cycle stages, or when 
exposed to stressors. Mitochondria can be long and filamentous, short and rod-like, and under 
conditions of compromised function, small and spherical (42, 35). Fusion and fission reactions 
control the number of mitochondria within a cell, and can also control mitochondrial morphology 
and organization (5). The heterogeneity in these organelles with regards to shape and 
intercellular arrangement can most often be attributed to the various functions and energy 
demands required of them by the cell in which they occupy. 
 
 2. Function 
A recent flourish in mitochondrial research has led to the discovery of additional 
important mitochondrial functions. As previously stated, the ER has a special membrane domain 
that interacts with the mitochondria referred to as the mitochondria-associated ER membrane. 
The proteins and enzymes within this region play important roles in calcium signaling (64). 
Mitochondrial calcium uptake has been shown to increase ATP production (53, 9), as well as 
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buffer the cytosolic calcium concentration (67). Regulation of the intracellular calcium 
concentration is critical for transcriptional regulation, metabolic processes, hormone release, and 
maintaining cell life or cell death signals (58, 30). Mitochondria also exhibit mechanisms of 
either inducing or inhibiting apoptosis. 
Apoptosis is a process where cells activate an organized cell suicide pathway leading to 
their breakdown and eventual phagocytosis. This is distinct from necrosis, and displays the 
morphological characteristics of cell shrinkage, membrane blebbing, and DNA cleavage and 
separation into apoptotic bodies with cell surface markers bringing about phagocytosis (39). 
Although additional mechanisms exist, the two most commonly characterized are the death 
receptor pathway, also known as the extrinsic pathway, and the mitochondrial pathway, also 
known as the intrinisic pathway. Both pathways ultimately lead to the activation of caspases, 
cysteine proteases that cleave after aspartate residues, which selectively cleave intracellular 
components resulting in cell death (65). Numerous cell stresses initiate the mitochondrial 
pathway including developmental cues, growth factor deprivation, ER stress, and DNA damage 
(27). The mitochondria respond by releasing the apoptosis inducing cytochrome c, as well as 
proapoptotic (Bax, Bak) and antiapoptotic (Bcl-2, Bcl-xL) members of the Bcl-2 family. The 
delicate interplay of these mitochondrial factors results in a controlled activation of caspases 
leading to apoptosis (48, 96, 21).  
Mitochondria also play a key role in maintaining cellular redox potential. In order to 
establish the electrochemical gradient and generate ATP, a series of redox reactions must take 
place, wherein electrons pass along a series of enzymes located in the inner membrane causing 
the release of free energy allowing the proton flux from the matrix to the intermembrane space. 
The coupling of ATP synthesis to the mitochondrial redox environment remains a topic of 
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debate. However, these redox reactions leading to oxidative phosphorylation, particularly the 
reoxidation of nicotinamide adenine dinucleotide (NADH) to NAD+, have clear implications on 
the mitochondrial redox environment (52). Alterations in the mitochondrial redox environment 
occur in numerous pathological conditions such as ischemic reperfusion injury and various 
cancers highlighting the importance of this mitochondrial function (43, 46).  
Mitochondria are most noted for their energy producing capabilities. Rightfully so, as on 
average the human body requires 50 kg of ATP turnover daily and the majority of this ATP is 
generated by oxidative phosphorylation in the mitochondria (3).  The enzyme complexes that 
comprise the ETC are comprised of multiple subunits that can be encoded for by the nuclear 
DNA or the mtDNA. 
 3. Genetics 
Almost all of the over 3000 proteins in mitochondria are coded for by nuclear DNA, 
transcribed, translated by cytosolic ribosomes, and then transported into the mitochondria. 
Effective nuclear-mitochondria cross talk is absolutely essential for normal mitochondrial 
function (94). Although nuclear DNA encodes for most of the human mitochondrial proteins, the 
circular, double stranded, and 16,569 bases in length human mtDNA molecule is responsible for 
37 genes including 22 tRNAs, 2 rRNAs, and 13 proteins. Human mtDNA contains very few 
introns, and is transcribed polycistronically. There are slight differences in the translation code 
that prevent nuclear DNA from being translated by mitoribosomes and vice versa (74). All 13 
proteins encoded for by mtDNA form subunits of ETC complexes, and are essential for normal 
oxidative phosphorylation.  
Mitochondrial genes are not inherited in the same fashion as nuclear genes. There is 
evidence to suggest that paternal mitochondria are actively tagged for degradation after 
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fertilization, and thus only the maternal mtDNA is inherited. This is known as a maternal 
inheritance pattern (33, 80). The complete mechanism of inheritance is not entirely understood, 
but it is widely accepted to follow a maternal lineage with only rare instances of paternal mtDNA 
being present after fertilization. 
The total number of mitochondrial genomes varies within different cell types, as well as 
within the mitochondria of one cell. Through a video-intensified photon counting microscope 
system, it was determined in human ovarian carcinoma cells that mitochondria contain a mtDNA 
copy number between 1 and 15 with most of the mitochondria containing between 2 and 6 copies 
(70). The total number of genomes per cell of course depends upon the number of mitochondria 
in the cell, which is largely dependent on the energy needs of the tissue type. For instance, 
leukocytes average 350 mtDNA copies per cell (49); where as myocardial cells average more 
than 6,000 mtDNA copies per cell (54). The mitochondrial genome also exhibits heteroplasmy, 
which is the presence of more than one type of mtDNA genome within a cell or individual.  
Heteroplasmy contributes heavily to certain genetic diseases, where the mutation burden 
of mtDNA determines the presence of the disease and occasionally the severity of the condition. 
The amount of mutated mtDNA must reach a certain threshold for certain diseases to occur. 
Copy number and heteroplasmy have also been implicated in age related illnesses, as both 
properties change in a tissue specific manner throughout an individual’s life span (91). The 
constant exposure to reactive oxygen species in the mitochondria makes the mtDNA particularly 
susceptible to mutations. Given the mitochondria’s diverse functional abilities and complex 
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B. Mitochondrial Diseases and Dysfunctions  
 1. Age Related Diseases 
Mitochondrial diseases have a wide spectrum of clinical presentations, as well as a 
variety of inheritance patterns such as maternal, Mendelian, or a combination of both. This can 
make generating a diagnosis rather difficult, as the same phenotype could be caused by a 
different mutation, and the same mutation could lead to a completely different condition 
depending on the quantity of the mutated mtDNA, or the cell type in which the mutation resides 
(73, 92). Despite this drastic variability, mitochondrial diseases generally affect tissues with 
high-energy requirements such the central nervous system, liver, kidneys, endocrine system, and 
skeletal and cardiac muscles (19). Dysfunctions within mitochondria most notably contribute to 
age related diseases, neurodegenerative diseases, and early and late onset genetic disorders. 
The process of aging is still somewhat a mystery, but problems in mitochondria have long 
been implicated as a possible causal agent. Aging results in a functional decline in various organ 
systems that coincide with a functional decline in the mitochondrial respiratory chain. It is also 
known that mtDNA mutations increase in aging animals and humans leading to mitochondrial 
dysfunction. An increase in reactive oxygen species (ROS) production is also observed (79). 
This has led to what is known as the Mitochondrial Free Radical Theory of Ageing (MFRTA). 
This theory attributes an increase in ROS to an increase in mtDNA damage, which leads to 
mitochondrial dysfunction and further ROS production ultimately resulting in aging (34). This 
theory is based on animal studies that suggest lower ROS levels result in longer lifespans. There 
are however some detractors from the MFRTA that suggest an increase in mtDNA mutations is 
the actual cause of aging, and the ROS increase is only supplementary. As evidence, studies have 
not shown a correlation between antioxidant defenses and life span (8). Further studies are 
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needed to elucidate the exact mechanisms of aging, but ROS and mtDNA mutation accumulation 
both seem to contribute. MtDNA mutations also play a role in several neurodegenerative 
diseases. 
 2. Neurodegenerative Diseases 
Spinal Muscular Atrophy (SMA) is a neuromuscular disorder characterized by skeletal 
muscle weakness and atrophy as a result of losing lower motor neurons in the spinal cord. Most 
cases are caused by a mutation in the survival motor neuron gene (SMN1). The quantity of 
mtDNA and respiratory chain enzyme activities are significantly reduced in the patient’s muscle 
tissues, which researchers regard as secondary to the original muscle wasting. However, there 
have been patients exhibiting the various pathologies associated with SMA while lacking a 
mutation in SMN1. These patients have depleted levels of mtDNA or mutations in the 
cytochrome c oxidase assembly gene resulting in their clinical phenotype (36). The entirety of 
this mechanism is not understood. 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. 
Evidence is mounting that mitochondrial dysfunction leads to the nigrostriatal neuronal cell 
death seen in both neurotoxin-induced and genetic mutant-associated forms of PD. Neurotoxins 
such as paraquat, rotenone, and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) directly 
inhibit mitochondrial complex I activities resulting in PD phenotypes. The neurotoxins also 
interfere with mitochondrial dynamic regulations leading to fragmented mitochondria due to 
increased fission reactions. The genetic form of PD sees mutations in nuclear genes that 
associate with vital mitochondrial functions such as mitophagy, mitochondrial dynamics, redox 
signaling, and mitochondrial protein import. As a result, ROS production is increased. Further 
evidence for mitochondrial dysfunction as a contributing factor to PD is seen when PD 
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phenotypes are reduced in animal models as a result of therapeutics targeted to inhibit 
mitochondrial dysfunction (50). Mitochondria are being investigated as a possible area of 
treatment for PD.  
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder, and it is 
characterized by a loss of cholinergic neurons leading to memory loss and behavioral 
impairments. Amyloid precursor protein and amyloid-β, which are found in mitochondrial 
membranes and associate with mitochondrial proteins, are elevated in AD and contribute to 
mitochondrial dysfunction. AD patients have mitochondria that produce excess ROS, have 
increased permeability, and reduced membrane potential. Excess amyloid precursor protein and 
amyloid-β may also affect mitochondrial dynamic fusion/fission, mitophagy, and disrupt the 
ETC (57). Potential therapeutics will likely need to address the mitochondrial dysfunction seen 
in AD patients. 
 3. Early and Late Onset Genetic Diseases 
Mitochondrial diseases as a whole have a prevalence of 1 in 5000 live births (72). 
Diseases may occur as a result of inherited mutations in nDNA or mtDNA, which has a 3-fold 
higher mutation rate respectively (86). Due to the multi-functional nature of mitochondria, 
mutations leading to dysfunction can result in abnormal calcium signaling, excessive ROS 
production, dysregulation of apoptosis, and of course energy deficiencies (97). Many conditions 
are multisystemic in nature, but some diseases are specific to one tissue type such as Leber’s 
hereditary optic neuropathy (LHON) (74). LHON leads to acute loss of central vision, and is 
most commonly the result of one of three possible homoplasmic point mutations in mtDNA 
genes that code for subunits in complex I (69). Most conditions, however, are caused by 
heteroplasmic mutations, where only some copies of the mtDNA have the mutation.  
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This is the case with MELAS (mitochondrial encephalomyopathy with lactic acidosis and 
stroke like episodes). 80% of MELAS cases are caused by the point mutation m.3243A>G, 
which affects mt-tRNALeu(UUR). The mutation results in a decreased rate of protein synthesis 
leading to energy deficiencies in addition to the symptoms included in the name of the disease. 
Although this mutation is shown to cause MELAS, relatively few patients with this mutation 
develop MELAS. Instead, maternally inherited diabetes and deafness (MIDD) is more 
commonly seen, as well as a mixture of symptoms from both MELAS and MIDD (55). This 
highlights the complexity of mitochondrial diseases, as they are dependent on numerous factors 
and often exhibit clinical heterogeneity. 
 Leigh’s disease (also known as subacute, necrotizing encephalopathy) is a mitochondrial 
condition that exhibits the largest genetic heterogeneity, and also shows great phenotypic 
variability. Leigh’s disease is characterized by focal, bilateral lesions in the basal ganglia, 
thalamus, brainstem, and other areas of the brain. Other symptoms associated with Leigh’s 
disease are muscle hypotonia, dystonia, seizures, ataxia, nystagmus, breathing irregularities, 
cardiomyopathy, gastrointestinal distress, and many others (2, 22). Mutations in nuclear or 
mitochondrial genes that code for subunits of the respiratory chain are the cause of Leigh’s 
disease.  
This research project focuses on the mutation m.8993 T>G. The mutation is present in 
the ATP6 gene of mitochondria, which codes for a subunit of the Fo component of ATP synthase. 
The m.8993 T>G mutation results in a substitution of arginine for leucine (85). It was originally 
believed that this mutation altered effective proton transfer, as it affects the pore-forming unit of 
ATP synthase (28). Other research suggests that the mutation affects the c ring subunits ability to 
rotate (77). With a mutation load above 95%, this mutation leads to Leigh’s disease typically 
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before the age of two. This same mutation at lower loads leads to an adult onset disorder known 
as NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa). The severity of the 
condition is often dependent on the percentage of mutated mtDNA (38). Because the m.8993 
T>G form of Leigh’s disease requires such a high percentage of mutated mtDNA and reduced 
phenotypes are seen at lower mutation loads, it is conceivable that altering the mutation burden 
could serve as a possible therapy. Only palliative care is available for Leigh’s disease and all of 
the previously discussed conditions. Mitochondrial dysfunction can lead to a vast amount of 
complex diseases. Cell based models provide an effective means of studying these diseases, and 
could possibly allow for patient specific treatments.  
 
C. Cell Based Models 
 1. Cybrid Model 
A lack of an effective model for studying mitochondrial disorders has led to a variety of 
inventive cell based model strategies in an attempt to mimic disease states. The first generation 
of these cell based models was the cytoplasmic hybrid (cybrid), which involved fusing mtDNA 
derived from platelets with mtDNA depleted neuroblastoma cells. Cybrids with mtDNA 
extracted from patients with AD, PD, and MELAS have been successful in displaying similar 
disease phenotypes to their respective pathologies including respiratory chain defects, increased 
oxidative stress, and alterations in calcium homeostasis (7, 24, 15). However, the cybrid model 
has the limitation that the host cells are tumor cells. These cells would thus be expected to have 
an altered cell cycle progression and mitochondrial biogenesis. Also, it is not known to what 
degree platelet derived mtDNA matches the genome of other cell types (90).  
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A modification of the cybrid model has been used to generate trans-mitochondrial mito-
mice. In this model, mutated (13997 G>A) mtDNA from mouse lung carcinoma cells was 
implanted in mtDNA depleted mouse embryonic stem cells (ESCs). The engineered ESCs were 
then implanted into pseudopregnant females, and the progeny were characterized as having 
successfully received the mutant mtDNA. The results displayed the expected complex I defects 
and lactate overproduction, but to a lesser degree than the mtDNA donor mouse lung carcinoma 
cells. In addition, other symptoms that were expected such as ROS overproduction, LHON 
phenotypes, and tumor formation were not observed (98). Although this model used ESCs as the 
host for the mutated mtDNA as opposed to tumor cells, the results did not fully display the 
expected disease state due to some compensatory mechanism. A human cell based model would 
need to be produced for further studies.  
 2. Neural Progenitor Model 
An improvement to the cybrid model for investigating neurodegenerative diseases is the 
use of human neural progenitor (hNP) cells. Neural progenitor cells can differentiate into 
neurons, astrocytes, and oligodendrocytes providing possible models for disease states and 
potential therapeutics for various conditions. Neural progenitors can be morphologically 
characterized by the formation of radially organized columnar epithelial cells known as “neural 
rosettes,” and possess a high nuclear-cytoplasmic ratio indicative of actively dividing cells (13, 
20). Gene expression or immunocytochemistry assays for markers such as Nestin, Musashi 1, 
SOX2, and polysialylated neural cell adhesion molecule also confirm cells as neural progenitors 
(14). Uniform neural progenitor populations can be created from hESCs when supplemented 
with select medium components. The development of these procedures was critical in being able 
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to generate an unlimited lineage-restricted cell source that can maintain a stable chromosome 
number for an effective cell based model (14, 78, 32).  
This new technology was used in the development of a model to study the genetic 
mitochondrial disease known as Leber’s hereditary optic neuropathy (LHON). In this study, 
neural progenitors were treated with dideoxycytidine (ddC), which reduces the endogenous 
mtDNA. There was no loss in hNP phenotypic markers after this procedure. The cells were then 
transfected with recombinant human mitochondrial transcription factor A complexed with 
mtDNA that harbored the pathogenic mtDNA G11778A mutation known to be a causal agent for 
LHON. The expression of the pathogenic RNA was confirmed, and the hNPs maintained their 
ability to differentiate after the transfection (31). Although successful in recreating this disease 
state, the challenges of this process are in ddC treating the hNPs while maintaining their hNP 
marker expression, and adequately transfecting the desired mutant DNA. This process may be 
difficult to replicate with more complex conditions, and thus alternatives were investigated. 
 3. Induced Pluripotent Stem Cell Model 
Reprogramming technologies allow researchers to create induced pluripotent stem cells 
(iPSCs) from adult cell types. These cells types exhibit prolonged self-renewal and the ability to 
differentiate into multiple cell lineages. Thus, iPSCs could serve as a cell-based model for drug 
screening, understanding disease mechanisms, and engineering patient specific cell lines for 
possible therapies (87). Reprogramming was first carried out via retroviral-mediated transfection 
of transcription factors known to be necessary for pluripotency (82, 83). Although successful in 
generating iPSCs for basic research, there was concern about using this technology for 
therapeutic applications, as the viral factors integrate with the genome causing the potential for 
cancers to develop. Excisable transposon and non-integrative plasmid strategies were 
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subsequently developed. These methods resolve the problem of genome integration, but are labor 
intensive and produce low yields of iPSCs (93, 68, 51). An improvement to these strategies is the 
use of modified mRNAs encoding the reprogramming factors OCT4, SOX2, c-MYC, KLF4, and 
LIN28A (93). In addition to taking fewer days and generating higher yields, mRNA 
reprogramming allows for dosage control of multiple proteins simultaneously, thus permitting 
much more control of the reprogramming process (51). It is also reasonable to conclude that 
upon further investigation, direct differentiation procedures can be developed using appropriate 
mRNAs (93).   
Reprogramming somatic cells from diseased patients to iPSCs has been used to generate 
effective cell-based models for neurodegenerative disorders such as SMA, PD, and Amyotrophic 
Lateral Sclerosis (99, 1, 16, 11). Recently this method has been applied to the study of cell-type 
specific disease phenotypes in the mitochondrial disease MELAS. As previously stated, it is 
known that the most common cause of MELAS is a mutation in the mtDNA. Reprograming has 
allowed for the study of how the mutation results in varying severities of clinical symptoms (29). 
In order for iPSCs to be used as an effective cell based model, it must be verified that 
reprogramming has not caused significant alterations to the genome. It has been shown that 
retroviral reprogramming led to mtDNA mutations that were not present in parental cells (63). 
This is a very important aspect to monitor before conclusions can be made in future studies. 
D. Summary 
The successful development of reprogramming technologies has enabled researchers to 
investigate diseases in a patient and cell specific manner. This method can be particularly useful 
in studying conditions that display clinical variability among patients, as well as conditions that 
affect certain cell types differently. As both conditions hold true in Leigh’s disease 8993 T>G, it 
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is our hope to develop an iPSC model that accurately reflects the disease characteristics seen in 
the patient from which the original cells were derived.   
Early reprogramming methods led to mutations that were not seen in the parent cell. 
Because mRNA reprogramming methods are still relatively new, it is not known if this process 
alters the genome of the reprogrammed cells. Before more investigative disease studies can be 
conducted with our Leigh’s 8993 T>G reprogrammed cell line, it must first be confirmed that the 
iPSCs maintain this mutation. Based on the background information, we propose to investigate 
the following specific aims. 
Specific Aim (I) Detect the presence of the 8993 T>G mtDNA mutation in iPSCs of various 
passage numbers and differentiated derivatives.  
This preliminary data is essential to ensure that the disease-causing agent is still present in the 
reprogrammed cells and differentiated cell types. 
Specific Aim (II) Quantify the mutation burden in patient derived fibroblasts, iPSCs of 
various passage numbers, and differentiated derivatives. 
This data will display the exact percentage of the 8993T>G mutation that is present in the 
mtDNA of the original patient derived fibroblasts, iPSCs, and differentiated derivatives. 
Experiments under this specific aim focus on investigating if the mutation burden is maintained 
through reprogramming, several passages, and differentiation into various cell types. The results 
of these experiments could provide support for this method as a viable option of developing 
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A. MtDNA Isolation 
Before the mtDNA can be sequenced, it must be isolated from whole cell pellets, 
purified, and quantified. 
 
Control Cell Lines Experimental Cell Lines 
Human Foreskin Fibroblast passage 13 
(BJ fib p13) 
Leigh’s Patient Fibroblast passage 7 
(FB1 fib p7) 
Induced Pluripotent Stem Cell passage 21 
(BJ iPSC p21) 
Leigh’s Induced Pluripotent Stem Cell 
passage 9 (FB1 iPSC p9) 
 Leigh’s Induced Pluripotent Stem Cell 
passage 15 (FB1 iPSC p15) 
 Leigh’s Induced Pluripotent Stem Cell 
passage 21 (FB1 iPSC p21) 
Induced Pluripotent Stem Cell that has been 
spontaneously differentiated passage 24 
(BJ Diff p24) 
Leigh’s Induced Pluripotent Stem Cell that 
has been spontaneously differentiated 
passage 24 (FB1 Diff p24) 
 
Table 1: List of cell samples used in all experiments. 
The FB1 samples were derived from a Leigh’s patient donor, and are expected to have the 8993 
T>G mutation. All of the BJ samples are expected to have the wild type 8993 T, thus, serving as 
the control. All samples will undergo the same processing. 
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Figure 1: Schematic of sample derivation prior to our experiments. 
The mRNA based reprogramming procedure was carried out according to established protocols 
(62), resulting in the generation of iPSCs. Spontaneous differentiation was carried out by 
embryoid body formation according to established protocols (37). This form of differentiation 
results in cell types from all three germ layers. These procedures were carried out prior to our 
experiments. 
  
                Control             BJ fib                     BJ iPSC                    BJ Diff 
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Figure 2: Schematic of mtDNA extraction. 
First, total DNA was extracted from whole cell pellet. MtDNA was then extracted by 
enzymatically degrading all non-circular forms of DNA. Finally, the region of interest within the 
ATP6 gene was PCR amplified.  
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 1. Extracting MtDNA From Whole Cell Pellets 
Cell pellets containing approximately 500,000 cells were removed from the freezer to 
thaw. The QIAamp DNA mini kit manufacturer protocol was followed to extract total DNA, and 
the details can be seen in Appendix i (Qiagen, Valencia, CA, USA). This results in an elution of 
80 µL of distilled water (dH2O) and total DNA from all cells. In order to obtain the circular 
mtDNA, all other DNA was degraded using the Plasmid-Safe ATP-Dependent DNase 
(Epicentre, Madison, WI, USA). This product selectively degrades all non-circular DNA 
molecules. The manufacturer recommended mini-preparation protocol was followed, details of 
which can be found in Appendix i. The 50 µL solutions containing the mtDNA were further 
treated with 1 µL of RNaseA for 1 hour at 37°C to further avoid any non-mtDNA nucleic acids. 
It is expected that at this point, the mtDNA should be intact, and all other forms of DNA should 
be degraded. The samples were further processed prior to use in sequencing protocols. 
 2. Further Purification and Gel Extraction 
In order to rid the mtDNA samples of previously used enzymes, salts, etc., the samples 
were cleaned using the UltraClean 15 DNA Purification Kit (Mo Bio, Carlsbad, CA, USA), 
details of the protocol can be found in Appendix ii. To ensure the mtDNA was maintained in a 
16kb circle, the samples were run on a 0.8% agarose gel, and the 16kb band that appeared for 
each sample was extracted from the gel. The methods for creating and running the gel, as well as 
the results can be found in Appendix ii. Because the samples were extracted from an agarose gel, 
they needed to be cleaned again using the UltraClean 15 DNA Purification Kit with a slightly 
modified protocol to get rid of the agarose, details of which are present in Appendix ii. With the 
mtDNA isolated and purified, the samples were prepared for sequencing. 
 
20 
Back To Table of Contents 
B. Sample Preparation for Sequencing 
The previous procedures resulted in a 30 µL solution of dH2O with an unknown quantity 
of mtDNA. The amount of mtDNA needed to be quantified and diluted to meet the specifications 
for Sanger sequencing and whole exome next-gen sequencing. 
 1. Quantification and Dilution 
The mtDNA was quantified using a NanoDrop One UV/Vis Spectrophotometer (Thermo 
scientific, Wilmington, DE, USA). A blank of 1.5 µL of dH2O was used to establish a zero, and 
1.5 µL of each sample was used to find the concentration. Concentration results can be found in 
Appendix iii. Exome sequencing requires approximately 25 ng of DNA, and the samples were 
diluted accordingly. Sanger sequencing, however, requires the area of interest (Region of ATP6 
gene containing 8993) to be PCR amplified, purified, and diluted to a concentration of 10ng/µL. 
 2. PCR and Preparations for Sanger Sequencing 
Primers were generated using the human mtDNA sequence provided by mitomap.org, 
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Table 2. Primer information for region of ATP 6 
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A standard PCR was carried out using the Takara Taq PCR Amplification Kit (Clontech, 
Mountain View, CA, USA). A detailed protocol of the reaction mixture and the cycle 
information can be seen in Appendix iv. 10 µL of the PCR product for each sample was run on a 
2% agarose gel to confirm proper amplification of the region of interest. The methods for 
creating and running the gel, as well as the results can be found in Appendix ii. After gel 
confirmation, the PCR products were cleaned again using the UltraClean 15 DNA Purification 
Kit (Mo Bio, Carlsbad, CA, USA). The cleaned PCR products were quantified using a NanoDrop 
One UV/Vis Spectrophotometer (Thermo scientific, Wilmington, DE, USA), and diluted to 10 
ng/µL with dH2O for Sanger sequencing. Also, the primers were diluted to 20ng/µL for Sanger 
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Figure 3: Sequence of amplified product.  
The 8993 position is denoted with an asterisk. We are expecting all of the BJ derived samples to 
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C. Sanger Sequencing, Next-gen Sequencing for Whole Exome, and Accompanying 
Sequence Analysis 
All sequencing was carried out in collaboration with the Virginia Commonwealth 
University Nucleic Acids Research Facility. 
 1. Sanger Sequencing and Analysis 
Sequencing reactions were carried out with the forward and reverse primers. The cycle 
sequencing reaction was carried out on a 96-capillary 3730XL (Applied Biosystems, Foster City, 
CA, USA) with BigDye Taq FS Terminator V 3.1. The genotyping and fragment sizing was done 
on a 3130XL (Applied Biosystems, Foster City, CA, USA). Details of the cycle sequencing 
reaction and the precipitation protocol can be seen in Appendix v. The files generated from the 
sequencing were observed using CodonCode Aligner (CodonCode Corporation, Centerville, 
MA, USA). 
 2. Next-gen Sequencing of Whole Exome and Analysis 
The DNA concentration was verified using a Qubit fluorometer (Thermo scientific, 
Wilmington, DE, USA). Instead of the standard DNA fragmentation, an enzymatic 
fragmentation was performed using the KAPA Frag Enzyme from the KAPA HyperPlus Library 
Preparation Kit (KAPA Biosystems, Wilmington, MA, USA). This alternative was performed in 
order to increase yield during the fragmentation step. Fragmented DNA was purified using 
Ampure beads (Beckman Coulter, Brea, CA, USA). DNA libraries were prepared using the 
Accel-NGS 2S Plus DNA Library Kit (Swift Biosciences, Ann Arbor, MI, USA). 10 PCR cycles 
were carried out during the Library Amplification step. The final libraries were analyzed with a 
2100 Bioanalyzer to assess library size distribution (Agilent Technologies, Santa Clara, CA). 
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DNA libraries were quantified with the KAPA Library Quantification Kit to ensure accuracy 
(KAPA Biosystems, Wilmington, MA, USA). Based on the qPCR results, the DNA libraries 
were compiled in equimolar amounts and sequenced with the HiSeq 2500 using TruSeq v3 
reagents according to the 2 x 100 bp protocol (Illumina, San Diego, CA, USA). 
The file generated from sequencing was separated out into FASTQ files using bcl2fastq 
software version 2.17 (Illumina, San Diego, CA, USA). These files were aligned to the mtDNA 
reference human genome 19 with Burrows-Wheeler Alignment Tool (45). The alignment tool 
generates Sequence Alignment Map (SAM) files, which are sorted based on the coordinates of 
the sequence. The SAM files are then converted to a compressed form, BAM format, using 
SAMTools. PCR duplicates were removed from the alignment using the Picard toolkit (Broad 
Institutes, Cambridge, MA, USA). Finally, the BAM format files were sent to Atlas2 to generate 
variant calling files (VCFs) (Human Genome Sequencing Center, Houston, TX, USA). 
Integrative Genomics Viewer (IGV) was used to view the sequences (88), while the VCFs were 




Back To Table of Contents 





A. Sanger Sequencing Results 
It was expected that the 8993 T>G mutation would be present in the original fibroblast 
taken from the Leigh’s disease patient, as well as in the iPSCs of various passage numbers and 
differentiated cells derived from the patient fibroblast. In order to confirm the presence of the 
mutation, the mtDNA was extracted from whole cell pellets, and our region of interest within the 
ATP6 gene was PCR amplified. The PCR product was purified and quantified to the appropriate 
specification. This allowed for Sanger sequencing of the specific ATP6 region containing the 
8993 site. All procedures were conducted as outlined in the materials and methods section. 
Sanger sequencing of our samples was necessary to confirm the presence of the disease causing 
mutation after reprogramming and spontaneous differentiation. The results demonstrate that the 
8993 T>G mutation is present in all FB1 samples (FB1 fib p7, FB1 iPSC p9, FB1 iPSC p15, FB1 
iPSC p21, and FB1 Diff p24). (Figure 4-6). Verifying the presence of the mutation was a 
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Figure 4: Sanger sequencing results of FB1 fibroblast (BJ fibroblast control).  
PCR amplified products were Sanger sequenced, and the sequencing results were viewed using 
CodonCode Aligner. The mutation is seen in the FB1 fibroblast sample, and not in the BJ 








Figure 5: Sanger sequencing of FB1 iPSC across multiple passages (BJ iPSC control).  
PCR amplified products were Sanger sequenced, and the sequencing results were viewed using 
CodonCode Aligner. The mutation is seen in all FB1 iPSC samples, and not in the BJ iPSC 









Figure 6: Sanger sequencing of FB1 differentiated (BJ Diff control).  
PCR amplified products were Sanger sequenced, and the sequencing results were viewed using 
CodonCode Aligner. The mutation is seen in the FB1 differentiated sample, and not in the BJ 
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B. Next-gen Sequencing for Whole Exome Results 
With the presence of the mutation confirmed, the percentage of mutation burden in each 
sample was measured using high-throughput Next-gen sequencing for whole exome. This 
strategy has previously been utilized to effectively measure heteroplasmies in the mitochondrial 
genome (10, 84, 47). The mtDNA was extracted from whole cell pellets, and then purified before 
sequencing. The sequencing results yielded a range of total sequence reads between 388 and 
2031 at the 8993 position in the different cell samples. This large of a sample size allows us to be 
confident about the percentages measured. As expected, BJ fib, BJ iPSC, and BJ Diff possessed 
mostly the wild type thymine with only a few sequences containing the mutated guanine. The 
Leigh’s patient sample FB1 fibroblast exhibited the mutation in 85 % of the sequences read. The 
iPSCs of various passage numbers and the differentiated cell sample displayed similar mutation 
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Position 8993 Mutation Percentages 
  
Figure 7: Heteroplasmy data for all samples at position 8993. 
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were 
compiled, and the results were analyzed with the Integrative Genomics Viewer. This allows us to 
view heteroplasmic sequences with an exact measure of the variants. The BJ samples exhibited 
very low amounts of the T>G mutation at the 8993 position, and the FB1 samples exhibited a 
8993 T>G mutation burden in the range of 80-88%. The variant calling files filter settings can be 

















BJ        
Diff 
FB1         
fib 




















Back To Table of Contents 
Sample Name Total Number Sequenced 
8993 





BJ fibroblast 689 689 0 0 
BJ iPSC 1812 1801 11 1 
BJ Differentiated 388 377 9 3 
     
FB1 fibroblast 548 84 464 85 
FB1 iPSC p9 1987 234 1753 88 
FB1 iPSC p15 2031 305 1726 85 
FB1 iPSC p21 589 92 497 84 
FB1 iPSC 
Differentiated 1000 203 797 80 
 
Table 3: Heteroplasmy data for all samples at position 8993. 
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were 
compiled, and the results were analyzed with the IGV. This allows us to view heteroplasmic 
sequences with an exact measure of the variants. The total number of reads per sample at the 
8993 position ranged between 388 and 2,031. This is more than enough reads to make accurate 
determinations for sample 8993 T>G mutation burden. The BJ samples displayed a mutation 
burden between 0-3%, and the FB1 samples displayed a mutation burden between 80-88%. The 
variant calling files filter settings can be seen in Appendix vi.    
 
33 
Back To Table of Contents 





Despite the mitochondrial genome being rather small, effectively researching the 
pathogenesis of mitochondrial diseases caused by mtDNA mutations has been difficult. Leigh’s 
disease has the added complexity of being dependent upon reaching a threshold of mutation 
burden in a tissue specific manner. Our methods included the use of Sanger sequencing, Next-
gen sequencing, and subsequent analysis of the results to confirm the presence of the 8993 T>G 
mutation in all Leigh’s patient derived cell samples. The mutation was detected in all FB1 
samples, and the mutation burden was maintained at a consistently elevated percentage through 
reprogramming, several passages, and spontaneous differentiation. Thus, our experiments have 
resulted in the creation of an iPSC line with a comparable mutation burden to that of the Leigh’s 
patient fibroblast from which it was derived. Generating this cell line with the disease-causing 
mutation intact is a very important step in confirming reprogramming technologies as a viable 
option of creating a cell based model for Leigh’s disease.  
Clinically, Leigh’s disease displays variability among patients and variability among 
different tissues within individual patients, which can complicate research. Our cell based model 
addresses both of these issues. An iPSC model can be created specific to a patient. The stem cells 
could then be directly differentiated into specific cell types of interest such as neurons or 
myocytes. Further experiments can be carried out to determine how the disease affects specific 
tissues on a molecular basis. This is a promising approach for the investigation of patient and 
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tissue specific pathophysiology, and for generating possible therapeutics for individual patients 
affected by Leigh’s disease and other mitochondrial diseases. The methods used in this study to 
successfully create this disease model could also be slightly altered in order to investigate other 
mitochondrial diseases. 
In addition to confirming the consistent mutation burden of 8993 T>G, the Next-gen 
sequencing results also identified a number of other heteroplasmic variants (Table 4). Due to the 
highly polymorphic nature of the mitochondrial genome, a number of these variants are 
characterized as normal sequence variants that are not likely to contribute to Leigh’s disease. 
Some of the variants displayed in the FB1 patient samples were also present in the BJ control 
samples in similar quantites (Table 5). Thus, it is unlikely that these sequence variants contribute 
to Leigh’s disease. Two other variants in the FB1 patient samples were also present in the BJ 
control samples, but in lower quantities (Table 6). When cross examined with the MitoMap 
reference, both of these sites were determined to be normal polymorphisms. Also, a number of 
sequence variants were associated with previously defined mitochondrial haplogroups. It is 
widely known that haplogroup designations are used in population genetics to denote people 
with a common ancestory. The haplogroups connected to the FB1 cell line are indicative of 
European ancestory, which correlates with the origin of the cell line used in this study (Table 7). 
It would be interesting to see if other patients with Leigh’s disease could be connected to similer 
haplogroups. This information could be beneficial in identifying at risk populations for Leigh’s 
disease. 
With the normal variants identified, there were a few remaining sites of interest for 
possible future studies (Table 8). The 310 T>C mutation is in the hypervariable II region of the 
mitochondrial genome. This control region of the genome is heavily concentrated with 
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polymorphisms that have inconclusive affects, but the 310 T>C mutation has been implicated in 
malignant melanoma, colorectal cancer, and breast cancer (17, 25, 89). The presence of this 
mutation is detected in these types of cancer patients at a statistically higher amount when 
compared to control populations. This mutation is expected to hinder replication or transcription 
of the mitochondrial genome, which could elevate ROS production (89). It is unclear how this 
mutation might affect Leigh’s disease. 
Another possible variant of interest is 12358 A>G, which is in the ND5 gene coding for 
subunit five of NADH dehydrogenase. This mutation  is present in a statistically significant 
higher number of sporadic Creutzfeldt-Jakob disease cases compared to controls. The mutation is 
reported to be correlated with altered brain pH values. It is hypothesized that this could be 
caused by a lack of coupling in complex I of the electron transport chain. This variant has not 
previously been implicated in Leigh’s disease. 
Our research was focused on the 8993 T>G mutation in the ATP6 gene, however, many 
Leigh’s disease cases are caused by mutations in genes that code for subunits of complex I. 
Next-gen sequencing of the FB1 Leigh’s patient cell line revealed ten sequence variants in genes 
that code for subunits of complex I. None of these variants have previously been mentioned as 
causes of Leigh’s disease, but it is not inconceivable that they could in some way contribute to 
the disease state. Cross referencing these variants with other Leigh’s patient sequencing results 
could allow for the determination of their importance to Leigh’s disease.  
  Our results have opened up a few avenues for future areas of research. Because Leigh’s 
disease has more drastic affects on neural cells and myocytes, a possible area of research would 
be to directly differentiate our iPSC line into these cell types. Specific transcription factors have 
been used to direct differentiation into neural cell types (40). Direct differentiation to 
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cardiomyocytes has been difficult in humans, but mouse embryonic fibroblasts have been 
directed into cardiomyocytes (18). Differentiation strategies are constantly improving. 
Sequencing studies could be performed again to ensure the 8993 T>G mutation is still intact.  
In addition to sequencing for heteroplasmies, another interesting area of research could 
be connecting the level of mutation burden to the degree of mitochondria dysfunction. Select 
biomarkers for mitochondrial dysfunction such as carnitine, pyruvic acid, and lactic acid have 
been used in the past to assess mitochondrial respiration. However, a technology has been 
developed that allows mitochondrial respiration and glycolysis to be measured simultaneously in 
live cells. The Seahorse XF(e)24 Extracellular Flux Analyzer can measure the oxygen 
consumption rate and lactic acid production rate, which are very accurate measures of 
mitochondrial function. It would be interesting to see if the level of mutation burden 



















72 G>A HVII 86 100 100 99 97 T 
149 T>C HVII 90 100 100 100 100 T 
*310 T>C HVII 20 18 28 25 18 T 
1720 G>A RNR2 87 97 98 99 96 C 
2707 G>A RNR2 88 100 100 100 96 A 
4793 A>G ND2 83 97 99 100 85 A 
*5231 G>A ND2 20 0 0 0 1 G 
*5417 G>A ND2 21 0 0 1 0 G 
7028 T>C COX1 67 99 99 100 94 C 
*10325 G>A ND3 1 0 0 0 18 G 
11719 A>G ND4 82 100 98 100 99 G 
*11914 G>A ND4 28 0 0 0 0 G 
*12358 A>G ND5 18 0 1 0 1 A 
*12372 G>A ND5 21 0 1 0 0 G 
12705 T>C  ND5 87 99 99 99 98 C 
12879 T>C ND5 10 0 0 1 0 T 
14766 T>C CYTB 81 100 100 99 86 C 
15067 T>C CYTB 11 0 0 0 0 T 
16172 C>T HVI 89 100 99 100 100 T 
16184 C>A HVI 83 84 98 99 80 C 
16257 C>T HVI 86 99 99 100 97 C 
16295 C>T HVI 88 99 98 100 95 C 
 
Table 4: Other sites of heteroplasmic variants in Leigh’s patient cell line. 
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were 
compiled, and the results were analyzed with the Integrative Genomics Viewer. This allows us to 
view heteroplasmic sequences with an exact measure of the variants. In addition to the 8993 site, 
the sequencing results yielded a number of other variants when compared to the human genome 
19 reference. Yellow highlighted variant sites indicate that the control samples contained this 
variant with similar percentages. Green highlighted variant sites indicate that the control samples 
contained this variant, however, the percentages of the variant in the control samples were much 
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lower than the percentages in the FB1 samples. The MitoMap nucleotide was included to 




































149 T>C HVII 90 100 100 100 100 99 100 100 T 
12705 T>C  ND5 87 99 99 99 98 99 100 100 C 
16172 C>T HVI 89 100 99 100 100 100 100 100 T 
16184 C>A HVI 83 84 98 99 80 97 88 91 C 
 
Table 5: Heteroplasmic variants in Leigh’s patient cell line similar in BJ control. 
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were 
compiled, and the results were analyzed with the Integrative Genomics Viewer. These four sites 
are the same yellow highlighted sites from Table 4. Because the BJ control samples contain these 
variants at similar quantities, it is likely that these are natural variants that do not contribute to 
Leigh’s disease. Cross referencing the variants with the MitoMap reference revealed that the 
12705 and 16172 sequences are considered normal polymorphisms. The variant calling files 




































2707 G>A RNR2 88 100 100 100 96 0 1 27 A 
14766 T>C CYTB 81 100 100 99 86 2 0 18 C 
 
Table 6: Heteroplasmic variants in Leigh’s patient cell line different in BJ control. 
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were 
compiled, and the results were analyzed with the Integrative Genomics Viewer. These sites are 
the same green highlighted sites from Table 4. Cross referencing the variants with the MitoMap 
reference revealed that both 2707 and 14766 are considered normal polymorphisms. The variant 
calling files filter settings can be seen in Appendix vi.   
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Sequence Variant Associated Haplogroup(s) 
4793 H7 
7028 Pre-HV, HV, N, R, U 








Table 7: Leigh’s patient sequence variant and associated haplogroup. 
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were 
compiled, and the results were analyzed with the Integrative Genomics Viewer. A number of the 
detected variants are associated with defined haplogroups. These haplogroups are associated with 
people of European descent, which makes sense as the Leigh’s patient donor is from Europe. It is 



















310 T>C HVII 20 18 28 25 18 T 
5231 G>A ND2 20 0 0 0 1 G 
5417 G>A ND2 21 0 0 1 0 G 
10325 G>A ND3 1 0 0 0 18 G 
11914 G>A ND4 28 0 0 0 0 G 
12358 A>G ND5 18 0 1 0 1 A 
12372 G>A ND5 21 0 1 0 0 G 
 
Table 8: Heteroplasmic variants possibly implicated in Leigh’s disease.  
The extracted mtDNA was subjected to whole exome next-gen sequencing. The sequencing 
results were compiled, and the results were analyzed with the Integrative Genomics Viewer. This 
table includes variants that were not ruled out by virtue of being consistent with the BJ control, 
MitoMap reference, or a known haplogroup. Sites 310 and 12358 are associated with other 
diseases, but it is unknown as to whether these variants or the any of the others contribute to 
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APPENDIX 
 
Appendix i: DNA mini kit protocol and mini-preparation ATP-Dependent DNase protocol 
 
Mini kit protocol 
1. Centrifuge thawed cell pellet for 5 minutes at 300 x g in a 1.5mL microcentrifuge tube. 
2. Remove the supernatant completely and discard without disturbing the cell pellet. 
3. Resuspend the cell pellet in 200 µL of phosphate buffered saline (PBS). 
4. Add 20 µL of proteinase K. 
5. Add 200 µL of buffer AL. Mix by pulse-vortexing for 15 seconds. 
6. Incubate solution at 56°C for 10 minutes 
7. Centrifuge to remove condensation from the lid. 
8. Add 200 µL of 100% ethanol, and pulse-vortex for 15 seconds. Centrifuge to remove 
drops from the lid. 
9. Apply mixture to QIAamp Mini spin column, and centrifuge at 6,000 x g for 1 minute.  
10. Discard the filtrate, and place the spin column in a new collecting tube. 
11. Add 500 µL of AW1 buffer to the spin column, and centrifuge at 6,000 x g for 1 minute.  
12. Discard the filtrate, and place the spin column in a new collecting tube. 
13. Add 500 µL of AW2 buffer to the spin column, and centrifuge at full speed 
(approximately 20,000 x g) for 3 minutes. 
14. Discard the filtrate, and centrifuge again at full speed for 1 minute. 
15. Place the spin column in a clean 1.5 mL microcentrifuge tube, and add 80 µL of nuclease 
free water. Incubate for 5 minutes. 
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16. Elute by centrifuging at 6,000 x g for 1 min.  
 
Mini-preparation ATP-Dependent DNase protocol 
Reaction Mixture  Amount (µL) 
Nuclease free H2O with total DNA 42 
25 mM ATP  2 
10X Reaction Buffer 5 
Plasmid-Safe DNase (10U) 1 
Total volume  50 
 
1. Incubate the reaction mixture for 30 minutes at 37°C. 
2. Inactivate DNase by incubating at 70°C.  
 
 
Appendix ii: UltraClean 15 DNA Purification protocol and gel protocols 
 
UltraClean 15 DNA purification protocol 
Purifying DNA from a solution 
1. Determine DNA solution volume (51 µL). 
2. Add 3 volumes of ULTRA SALT (153 µL) and mix well. 
3. Resuspend ULTRA BIND by vortexing for 1 minute or until homogenous. 
4. Add ULTRA BIND. 5 µL plus 1 µL per µg of DNA you expect to recover (6 µL). 
5. Incubate for 5 minutes at room temperature. Flick the tube, or invert the tube several time 
to insure proper mixing. 
6. Centrifuge for 5 seconds, and discard the supernatant. 
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7. Let the pellet soak in 1 ml of ULTRA WASH/ETHANOL for 5 minutes. Do not vortex 
DNA larger than 15 kb to avoid shearling.  
8. Centrifuge for 5 seconds, and discard supernatant.  
9. Centrifuge for 5 seconds again, and remove all traces of the ULTRA WASH/ETHANOL. 
10. Resuspend the pellet in 30 µL of nuclease free H2O by gently pipetting.  
11. Incubate for 5 minutes at room temperature. 
12. Centrifuge for 1 minute. 
13. Remove supernatant and transfer to a new clean 1.5 mL microcentrifuge tube. 
 
Purifying DNA from a TBE buffered agarose gel 
1. Determine weight of agarose gel band slice. 
2. Add ½ volume of ULTRA MELT and 4.5 volumes of ULTRA SALT, and mix well. 
3. Incubate at 55°C for approximately 5 minutes, or until gel is completely melted. 
4. Follow steps 3-13 from the above protocol on purifying DNA from solution. 
 
0.8% agarose gel preparation  
1. Dissolve 1.4g of ultra-pure agarose in 175 ml of TBE buffer. Heat until agarose dissolves 
completely into solution. Let the solution cool to approximately 50°C. 
2. Add 10.5 µL of ethidium bromide and stir under exhaust hood. 
3. Pour the gel solution into a gel with the appropriate size gel comb in place. Let the 
solution cool. 
4. Once the gel has solidified, pull the comb out without breaking the gel. 
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5. Mix 20 µL of cleaned up mtDNA with 3.33 µL of loading dye, and load the mix into the 
wells. 
6. Load an appropriate gel ladder. Run the gel at 30 V for 8-10 hours. Low voltage run to 
avoid smearing the large 16 kb band. 
7. Use the gel dock reader to extract the band. 
 
2.0% agarose gel preparation 
1. Dissolve 2g of ultra-pure agarose in 100 ml of TBE buffer. Heat until agarose dissolves 
completely into solution. Let the solution cool to approximately 50°C. 
2. Add 6 µL of ethidium bromide and stir under exhaust hood. 
3. Pour the gel solution into a gel with the appropriate size gel comb in place. Let the 
solution cool. 
4. Once the gel has solidified, pull the comb out without breaking the gel. 
5. Mix 10 µL of PCR amplified product with 1.67 µL of loading dye, and load the mix into 
the wells. 
6. Load an appropriate gel ladder. Run the gel at 80 V for 1.5 hours.  
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2.0 % agarose gel results 
 
 
Hyperladder ii was used as a reference (Bioline, Taunton, MA, USA). 
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Appendix iii: NanoDrop results  
 
NanoDrop concentration results after gel extraction 
Sample Name Concentration (ng/µL) 
H9 p54 73.1 
BJ FB p13 58.7 
BJ iPSC p21 281.1 
BJ Diff p24 35.6 
FB1 p7 125.1 
FB1 iPSC p9 79.0 
FB1 iPSC p15 24.6 
FB1 iPSC p21 44.1 





NanoDrop concentration results after PCR amplification 
Sample Name Concentration (ng/µL) 
H9 p54 88.3 
BJ FB p13 62.5 
BJ iPSC p21 62.7 
BJ Diff p24 35.3 
FB1 p7 128.8 
FB1 iPSC p9 104.7 
FB1 iPSC p15 38.6 
FB1 iPSC p21 34.3 
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Appendix iv: PCR protocol and cycle information 
 
PCR Reaction Setup  Stock Conc. 
 Volume per 
50 µl Rxn  
Final 
Conc. 
10x PCR buffer 10 5 1 
dNTP mixture 2.5 4 0.2 
10uM Forward primer 10 1 0.2 
10uM Reverse primer 10 1 0.2 
Takara Taq 250 0.25 1.25 
dd H20   38.25   
0.5 ng/50µl DNA  1 0.5 7.5 
Total volume   50   
 
 
Cycling Steps Temperatures and Times Cycles 
Denaturation 30 sec at 94°C 
25  Annealing 30 sec at 55°C 
Extension 30 sec at 72°C 
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Appendix v: Cycle sequencing reaction and precipitation protocol 
Cycle sequencing reaction for standard quarter reaction 
Sequencing Reaction Setup  Amount 
Big Dye 2 µl 
Primer X µl 3.2 pmol 
Sequencing buff (5X)  1 µl 
dd H20 X µl 
DNA  X µl 60-100 ng 
Total volume 10  
 
Precipitation Protocol 
1. Prepare 3 µl sodium acetate anhydrous (3M pH 4.6), 62.5 µl Ethanol (100 %), 14.5 µl 
water. 
2. Add 10 µl of water to make the sequencing samples up to 20 µl. 
3. Mix the sodium acetate anhydrous and ethanol with each sequencing sample. 
4. Centrifuge for 30 minutes. 
5. Remove the supernatant and add 250 µl of 70% ethanol. 
6. Centrifuge for 3-5 minutes. 
7. Remove supernatant and repeat 70% ethanol wash. 
8. Remove supernatant completely. 
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Appendix vi: Variant Calling Files filter settings 
In order to be included, sequences must be: 
1. SNP posterior probability higher than 0.95 
2. Number of variant reads greater than 3 
3. Variant read ratio greater than 0.1 
4. All variants are in a single strand direction 
5. Total coverage must be greater than 30 
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